Welcome To nibm
National Institutes of Biotechnology Malaysia (NIBM) is a consortium of three national biotechnology institutes – Malaysian Institute of Pharmaceuticals & Nutraceuticals (IPHARM), Agro-Biotechnology Institute Malaysia (ABI), and Malaysia Genome & Vaccine Institute (MGVI), established on 27 January 2012 as a Company Limited by Guarantee (CLG), an autonomous not-for-profit entity to administer IPHARM, ABI and MGVI.
In 2011, the Cabinet agreed that ABI, IPHARM and MGVI be corporatised into a new autonomous not-for-profit body to enable the three institutes to be operated centrally, more effectively and efficiently. The entity is named as the National Institutes of Biotechnology Malaysia (NIBM).
The main objective of NIBM is to enable IPHARM, ABI and MGVI to minimise or eliminate government procedural requirements and replaced with a dynamic, fast & efficient decision-making process.
Among the roles of NIBM are to set priorities and direction for R&D activities, to plan for commercialization of R&D outputs and to enhance the R&D ecosystem to drive Malaysia into a global biotechnology hub. The management of NIBM will be centralised by Headquarter Office (HQ)